Constantine S Mitsiades Selected Research

Bortezomib (Velcade)

1/2021	M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models.
10/2018	An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
3/2014	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
2/2014	Future agents and treatment directions in multiple myeloma.
10/2013	Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
5/2013	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
7/2012	Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.
4/2012	Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
1/2012	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
2/2011	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Constantine S Mitsiades Research Topics

Disease

79	Multiple Myeloma 01/2021 - 01/2002
74	Neoplasms (Cancer) 01/2021 - 06/2002
8	Hematologic Neoplasms (Hematological Malignancy) 11/2009 - 03/2004
8	Thyroid Neoplasms (Thyroid Cancer) 12/2007 - 08/2002
6	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2004
5	Retinoblastoma (Glioblastoma, Retinal) 09/2009 - 12/2002
4	Carcinoma (Carcinomatosis) 12/2009 - 09/2006
3	Leukemia 01/2021 - 04/2010
3	Breast Neoplasms (Breast Cancer) 01/2021 - 02/2011
3	Fatigue 01/2012 - 06/2010
3	Medullary Carcinoma 12/2009 - 05/2005
3	Waldenstrom Macroglobulinemia (Macroglobulinemia) 05/2009 - 04/2003
3	Lymphoma (Lymphomas) 12/2005 - 01/2005
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 10/2006
2	Bone Diseases (Bone Disease) 01/2021 - 01/2012
2	Carcinogenesis 10/2018 - 02/2011
2	Hypoxia (Hypoxemia) 01/2018 - 11/2003
2	Thrombocytopenia (Thrombopenia) 07/2012 - 01/2012
2	Diabetic Retinopathy (Retinopathy, Diabetic) 10/2009 - 08/2004
2	Leukostasis 10/2009 - 08/2004
2	Anaplastic Thyroid Carcinoma 10/2006 - 10/2003
2	Neoplasm Metastasis (Metastasis) 09/2006 - 07/2004
2	Chromosomal Instability (Chromosome Stability) 01/2003 - 07/2002
1	Neuroblastoma 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Residual Neoplasm 01/2021

Drug/Important Bio-Agent (IBA)

30	Bortezomib (Velcade)FDA Link 01/2021 - 09/2002
19	Proteasome InhibitorsIBA 01/2021 - 06/2002
15	Dexamethasone (Maxidex)FDA LinkGeneric 03/2014 - 03/2002
14	Lenalidomide (CC 5013)FDA Link 01/2021 - 06/2004
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
13	Thalidomide (Thalomid)FDA Link 01/2014 - 06/2002
12	Pharmaceutical PreparationsIBA 01/2021 - 05/2004
11	NF-kappa B (NF-kB)IBA 04/2010 - 06/2002
10	Biological ProductsIBA 01/2021 - 01/2002
7	Insulin-Like Growth Factor I (IGF-1)IBA 10/2006 - 08/2002
6	LigandsIBA 01/2018 - 03/2002
6	Immunomodulating AgentsIBA 06/2015 - 04/2009
6	Vorinostat FDA Link 07/2013 - 04/2003
6	Histone Deacetylase InhibitorsIBA 07/2013 - 04/2003
6	Antineoplastic Agents (Antineoplastics)IBA 11/2012 - 02/2006
6	Phosphotransferases (Kinase)IBA 01/2011 - 03/2004
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2003
5	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2017 - 10/2002
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2012 - 03/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2012 - 03/2003
4	Transcription Factors (Transcription Factor)IBA 01/2016 - 06/2002
4	CytokinesIBA 10/2013 - 07/2002
4	GlucocorticoidsIBA 07/2012 - 01/2005
4	tanespimycin (17AAG)IBA 02/2011 - 02/2006
4	Neutralizing AntibodiesIBA 10/2009 - 03/2004
4	AndrogensIBA 09/2006 - 03/2004
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021 - 06/2006
3	Histone Deacetylases (Histone Deacetylase)IBA 07/2013 - 01/2004
3	Melphalan (Alkeran)FDA LinkGeneric 07/2012 - 03/2003
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 02/2011 - 10/2002
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2009 - 05/2005
3	Complementary DNA (cDNA)IBA 10/2009 - 05/2005
3	Death Domain ReceptorsIBA 06/2006 - 01/2005
3	Caspase 8 (Caspase-8)IBA 06/2006 - 01/2005
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 06/2006 - 11/2003
3	geldanamycinIBA 02/2006 - 04/2003
3	Interleukin-6 (Interleukin 6)IBA 08/2005 - 07/2002
3	Insulin-Like PeptidesIBA 03/2004 - 07/2002
2	AntibodiesIBA 01/2022 - 08/2005
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 09/2011
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2021
2	PanobinostatIBA 01/2021 - 07/2013
2	Hormones (Hormone)IBA 01/2021 - 11/2012
2	RNA (Ribonucleic Acid)IBA 01/2021 - 03/2007
2	ixazomibIBA 01/2021 - 10/2018
2	Histones (Histone)IBA 07/2014 - 11/2009
2	Estrogen ReceptorsIBA 07/2014 - 02/2006
2	LuciferasesIBA 10/2013 - 04/2010
2	Caspase 3 (Caspase-3)IBA 10/2013 - 12/2009
2	Peptides (Polypeptides)IBA 09/2012 - 03/2004
2	Diphosphonates (Bisphosphonates)IBA 01/2012 - 09/2006
2	Zoledronic Acid (Zometa)FDA Link 01/2012 - 09/2006
2	DepsipeptidesIBA 06/2010 - 07/2008
2	plitidepsin (aplidine)IBA 06/2010 - 07/2008
2	Imatinib Mesylate (Gleevec)FDA Link 04/2010 - 10/2003
2	Alkylating AgentsIBA 07/2008 - 07/2007
2	CaspasesIBA 10/2007 - 05/2005
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 09/2006 - 07/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2005 - 03/2004
2	Monoclonal AntibodiesIBA 06/2005 - 01/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2004 - 11/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2003 - 07/2002
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022
1	Androgen Antagonists (Antiandrogens)IBA 01/2021
1	Hepatitis B e AntigensIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Cyclin-Dependent Kinase 9IBA 01/2021
1	peptidase 7IBA 01/2021
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2021

Therapy/Procedure

38	Therapeutics 01/2022 - 04/2003
12	Drug Therapy (Chemotherapy) 01/2021 - 03/2002
4	Immunotherapy 01/2022 - 10/2013
2	Stem Cell Transplantation 06/2015 - 02/2009